



## INDEPENDENT AUDITORS' REPORT

To

The Members of **Ratnatris Pharmaceuticals Private Limited**

### Report on the audit of the financial statements

#### Opinion

1. We have audited the accompanying financial statements of **Ratnatris Pharmaceuticals Private Limited** (formally know as Ratnamani Healthcare Pvt Ltd.) ("the Company"), which comprise the balance sheet as at **March 31, 2022**, and the Statement of Profit and Loss and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.
2. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ('Act') in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at **March 31, 2022**, its profit (or Loss) and cash flows for the year ended on that date.

#### Basis for opinion

3. We conducted our audit in accordance with the standards on auditing specified under section 143 (10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Company in accordance with the code of ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the code of ethics.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



### **Material Uncertainty Related to Going Concern**

The Company's net worth is negative. We were informed that the Company is also in the process of identifying alternative business plans to improve the performance of the Company.

The above factors cast a significant uncertainty on the Company's ability to continue as a going concern. Pending the resolution of the above uncertainties, the Company has prepared the aforesaid statement on a going concern basis.

### **Key audit matters**

4. Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Reporting of key audit matters as per SA 701, Key Audit Matters are not applicable to the Company as it is an unlisted company.

### **Information other than the financial statements and auditors' report thereon**

5. The Company's board of directors is responsible for the preparation of the other information. The other information comprises the information included in the Board's Report including Annexures to Board's Report, Business Responsibility Report but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.





If, based on the work we have performed, we conclude that there is a material misstatement of this other information we are required to report that fact. We have nothing to report in this regard.

### **Management's responsibility for the financial statements**

6. The Company's board of directors are responsible for the matters stated in section 134 (5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.
7. In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The board of directors are also responsible for overseeing the Company's financial reporting process.

**8. Scheme of Compromised and Arrangement approved by Honorable NCLT on 20/09/2022.**

**The financial statements have been prepared basis on the Scheme of Compromised and Arrangement as approved by Honorable NCLT and order passed on dt. 20/09/2022.**

**The auditors have consider the entire scheme of Compromised and Arrangement and accordingly the financial statement have been audited for the ended 31/03/2022.**



## **Auditor's responsibilities for the audit of the financial statements**

8. Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
9. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
  - Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
  - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls
  - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
  - Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty





exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
10. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
  11. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
  12. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

### **Report on other legal and regulatory requirements**

13. As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the **Annexure "A"**, a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
14. As required by Section 143(3) of the Act, we report that:



- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;
- (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
- (c) The balance sheet, the statement of profit and loss, and the cash flow statement dealt with by this report are in agreement with the books of account;
- (d) In our opinion, the aforesaid financial statements comply with the accounting standards specified under section 133 of the Act, read with rule 7 of the Companies (Accounts) Rules, 2014;
- (e) On the basis of the written representations received from the directors as on **March 31, 2022** taken on record by the board of directors, none of the directors is disqualified as on **March 31, 2022** from being appointed as a director in terms of Section 164 (2) of the Act;
- (f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "**Annexure B**". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting;
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us;
  - a. The Company has pending litigations which would not impact on its financial position in its standalone financial statements. The details are as under ;




**Income Tax Liabilities:**

<b>Assessment Year</b>	<b>Original Demand (Rs. In lacs)</b>	<b>Demand Outstanding (Rs.in lacs)</b>	<b>Remarks</b>
2018-19	462.93 lacs	462.93 lacs	A writ petition has been filed before Honorable Gujarat High Court, Ahmedabad against the order of the Assessing officer ignoring the facts and details submitted during the course of Assessment proceedings.

- b. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses; and
- c. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company

**For RAJESH J. SHAH & ASSOCIATES  
CHARTED ACCOUNTANTS  
FRN 108407W**



**CA RAJESH J. SHAH  
PARTNER  
M.No. : 040268**



**UDIN : 22040268AWUFMW3098**

**Place : Ahmedabad  
Date : 23<sup>rd</sup> September, 2022.**



## **ANNEXURE A- Report under the Companies (Auditor's Report) Order, 2020**

### **Referred to in of our report of even date**

In terms of the information and explanations sought by us and given by the company and the books and records examined by us in the normal course of audit and to the best of our knowledge and belief, we state that: -

- i) a) (A) The company has maintained proper records showing full particulars including quantitative details and situation of Property, Plant and Equipment.
- (B) The Company has possess Intangible Assets.
- b) Some of the Property, Plant and Equipment and capital work-in-progress were physically verified during the year by the Management in accordance with a program of verification, which in our opinion provides for physical verification of all the Property, Plant and Equipment and capital work-in-progress at reasonable intervals having regard to the size of the Company and the nature of its activities. According to the information and explanations given to us no material discrepancies were noticed on such verification.
- c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties (other than immovable properties where the Company is the lessee and the lease agreements are duly executed in favour of the lessee) disclosed in the standalone financial statements are held in the name of the Company.
- d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not revalued its Property, plant and equipment (including Right-of-use assets) or Intangible assets or both during the year.
- e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no proceedings initiated or pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.
- ii) a) The inventory has been physically verified by the management during the year. In our opinion, the frequency of such verification is reasonable and procedures and coverage as followed by management were appropriate. No discrepancies were noticed on verification between the physical stocks and





the book records that were 10% or more in the aggregate for each class of inventory.

b) According to the information and explanations given to us, at any point of time of the year, the Company has been sanctioned working capital facility excess of five corers rupee in aggregate, from banks on the basis of security current assets. In our opinion, the quarterly returns or statements filed by the Company with such banks are in agreement with the books of account of the Company.

- iii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any investments, provided guarantee or security or granted any advances in the nature of loans, secured or unsecured, to companies, firms, limited liability partnerships or any other parties during the year.
- iv) The company has not given any loans, investments guarantees, and security In respect of loans, investments guarantees, and security the provisions of section 185 and 186 of the Companies Act, 2013 have been complied with.
- v) The Company has not accepted any deposits or amounts which are deemed to be deposits from the public. Accordingly, clause 3(v) of the Order is not applicable.
- vi) The maintenance of cost records has been specified by the Central Government under section 148(1) of the Companies Act, 2013. We have broadly reviewed the books of account maintained by the Company pursuant to the Companies (Cost Records and Audit) Rules, 2014, as amended prescribed by the Central Government for maintenance of cost records under Section 148(1) of the Companies Act, 2013, and are of the opinion that, prima facie, the prescribed cost records have been made and maintained by the Company. We have, however, not made a detailed examination of the cost records with a view to determine whether they are accurate or complete.
- vii) a) The Company does not have any liability in respect of Sales tax, Service tax, Duty of excise and Value added tax during the year since effective 1 July 2017, these statutory dues has been subsumed into GST.

According to the information and explanations given to us and on the basis of our examination of the records of the Company, amounts deducted/ accrued in the books of account in respect of undisputed statutory dues including Goods and Services Tax ('GST'), Provident fund, Employees' State Insurance, Income-tax, Cess and other material statutory dues have generally been regularly deposited with the appropriate authorities.



According to the information and explanations given to us, no undisputed amounts payable in respect of GST, Provident fund, Employees' State Insurance, Income-tax, Duty of Customs, Cess and other material statutory dues were in arrears as at **31 March 2022** for a period of more than six months from the date they became payable.

b) According to the information and explanations given to us, there are no dues of GST, Provident fund, Employees' State Insurance, Income-tax, Sales tax, Service tax, Duty of Customs, Value added tax, Cess or other statutory dues which have not been deposited by the Company on account of disputes, except for the following :

<b>Name of the Statute</b>	<b>Nature of Dues</b>	<b>Amount ( in Lacs)</b>	<b>Period to which the amount relates</b>	<b>Forum where dispute is pending</b>
Income tax Act, 1961	Income tax	462.93	2018-19	High Court

viii ) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income-tax Act, 1961 as income during the year.

ix ) a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not defaulted in the repayment of loans or other borrowings or in the payment of interest thereon to any lender during the year.

b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the company has not been declared willful defaulter by any bank or financial institution or government or any government authority.

c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has taken a term loan during the year and it is unutilized for the purpose for which term loan has taken.

d) According to the information and explanations given to us and on an overall examination of the balance sheet of the Company, we report that no funds have been raised on short-term basis and utilized for long term basis by the Company. Accordingly, clause 3(ix)(d) of the Order is not applicable.





- e) According to the information and explanations given to us and on an overall examination of the financial statements of the Company, we report that the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries as defined under the Companies Act, 2013. Accordingly, clause 3(ix)(e) of the Order is not applicable.
- f) According to the information and explanations given to us and procedures performed by us, we report that the Company has not raised loans during the year on the pledge of securities held in its subsidiaries as defined under the Companies Act, 2013. Accordingly, clause 3(ix)(f) of the Order is not applicable.
- x ) a) The Company has not raised any moneys by way of initial public offer or further public offer (including debt instruments). Accordingly, clause 3(x)(a) of the Order is not applicable.
- b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has made 6,31,800/- 0% Unsecured fully Compulsory Convertible Debentures (CCDs) Series – 1 face value of Rs. 10/- each during the year.
- xi ) a) Based on examination of the books and records of the Company and according to the information and explanations given to us, considering the principles of materiality outlined in Standards on Auditing, we report that no fraud by the Company or on the Company has been noticed or reported during the course of the audit.
- b) According to the information and explanations given to us, no report under sub-section (12) of Section 143 of the Companies Act, 2013 has been filed by the auditors in Form ADT-4 as prescribed under Rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.
- c) As represented to us by the Management, there were no whistle blower complaints received by the Company during the year and upto the date of this report.
- xii ) According to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, clause 3(xii) of the Order is not applicable.
- xiii ) Based upon the audit procedures performed and according to the information and explanations given to us, All transactions with related parties are in compliance with sections 177 and 188 of Companies Act, 2013 where applicable and the details have been disclosed in the Financial statements etc. as required by the applicable accounting standards.



- xiv ) a) Based on examination of the books and records of the Company and according to the information and explanations given to us, Internal audit under sec 138 of Companies Act, 2013 is not applicable to the Company. Accordingly, clause 3(xiv) of the Order is not applicable, However, The Company has in-house internal audit system.
- xv ) In our opinion and according to the information and explanations given to us, the Company has not entered into any non-cash transactions with its directors or persons connected to its directors and hence, provisions of Section 192 of the Companies Act, 2013 are not applicable to the Company.
- xvi ) a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(a) of the Order is not applicable.
- b) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(b) of the Order is not applicable.
- c) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable.
- d) According to the information and explanations provided to us during the course of audit, the Group does not have any CIC. Accordingly, the requirements of clause 3(xvi)(d) are not applicable.
- xvii) The Company has incurred cash losses in the current and in the immediately preceding financial year.
- xviii) There has been no resignation of the statutory auditors during the year. Accordingly, clause 3(xviii) of the Order is not applicable.
- xix ) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that the Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future






viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

xx ) In our opinion and according to the information and explanations given to us, there is no unspent amount under sub-section (5) of Section 135 of the Companies Act, 2013 pursuant to any project. Accordingly, clauses 3(xx)(a) and 3(xx)(b) of the Order are not applicable.

**For RAJESH J. SHAH & ASSOCIATES**  
**CHARTERED ACCOUNTANTS**  
**FRN-108407W**



**CA RAJESH J. SHAH**  
**PARTNER**  
**M.No.040268**

**PLACE : AHMEDABAD**  
**DATE : 23<sup>rd</sup> September, 2022**

## **Annexure "B" to the Independent Auditor's Report**

(Referred to in paragraph 2 (f) under 'Report on other legal and regulatory requirements' section of our report to the Members of **Ratnatris Pharmaceuticals Private Limited** of even date)

### **Report on the internal financial controls over financial reporting under clause (i) of sub – section 3 of section 143 of the Companies Act, 2013 ("the Act")**

We have audited the internal financial controls over financial reporting of **Ratnatris Pharmaceuticals Private Limited** ("the Company") as at **March 31, 2022**, in conjunction with our audit of the financial statements of the Company for the year ended on that date.

### **Management's responsibility for internal financial controls**

The board of directors of the Company is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

### **Auditors' responsibility**

Our responsibility is to express an opinion on the internal financial controls over financial reporting of the Company based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India and the standards on auditing prescribed under Section 143 (10) of the Companies Act, 2013, to the extent





applicable to an audit of internal financial controls. Those standards and the guidance note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement in the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial control system over financial reporting.

### **Meaning of internal financial controls over financial reporting**

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.




### **Limitations of internal financial controls over financial reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management of override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### **Opinion**

In our opinion and according to the information and explanations given to us, the Company has, in all material respects, an adequate internal financial control system over financial reporting and such internal financial controls over financial reporting were operating effectively as at **March 31, 2022**, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

**For RAJESH J. SHAH & ASSOCIATES**  
**CHARTED ACCOUNTANTS**  
**FRN 108407W**

  
**CA RAJESH J. SHAH**  
**PARTNER**  
**M.No. 040268**



**Place : Ahmedabad**  
**Date : 23<sup>rd</sup> September, 2022.**



**RATNATRIS PHARMACEUTICALS PRIVATE LIMITED**  
(Formally known as RATNAMANI HEALTHCARE PRIVATE LIMITED)

CIN : U24230GJ2005PTC047394

REGISTERED OFFICE ADDRESS : 1004-1006, 10th Floor, North Tower, One42, Off Bopal Ambli road, Bodakdev, Ahmedabad GJ 380054 INDIA

**Balance Sheet as at March 31, 2022**

		Amount in ` '000		
PARTICULARS		NOTE NO	As at March 31, 2022	As at March 31, 2021
I	<b>EQUITY AND LIABILITIES</b>			
1	<b>Shareholder's funds</b>			
	(a) Share capital	3	18,766.36	18,000.00
	(b) Reserves and Surplus	4	1,11,497.35	(2,51,324.36)
	(c) Money received against share warrants			
	<b>Total Shareholder's funds</b>		<b>1,30,263.71</b>	<b>(2,33,324.36)</b>
2	<b>Share application money pending allotment</b>			
3	<b>Non current liabilities</b>			
	(a) Long term borrowings	5	8,36,416.03	13,05,223.13
	(b) Deferred tax liabilities (net)	16	-	-
	(c) Other long term liabilities	6	12,081.65	12,071.97
	(d) Long term - provisions	7	1,17,185.93	-
	<b>Total Non-current liabilities</b>		<b>9,65,683.61</b>	<b>13,17,295.10</b>
4	<b>Current liabilities</b>			
	(a) Short term borrowings	8	78,983.19	1,30,290.84
	(b) Trade payables	9		
	(A) Total outstanding dues of micro enterprises small enterprises		-	-
	(B) Total outstanding dues of creditors other than micro and small enterprises		3,29,156.07	1,91,867.52
	(c) Other current liabilities	10	25,875.97	16,461.70
	(d) Short term provisions	11	-	-
	<b>Total current liabilities</b>		<b>4,34,015.23</b>	<b>3,38,620.07</b>
	<b>Total Equity and Liabilities</b>		<b>15,29,962.54</b>	<b>14,22,590.80</b>
II	<b>ASSETS</b>			
1	<b>Non current assets</b>			
	(a) Property, Plant and Equipment and Intangible Assets			
	(i) Property, Plant and Equipment	12	5,71,784.74	7,20,479.79
	(ii) Intangible Assets	13	152.18	257.59
	(iii) Capital work-in-progress	14	-	-
	(iv) Intangible Assets under development	15	-	-
	(b) Non current investments	16	64.24	60.85
	(c) Deferred tax assets (net)	17	83,944.16	1,45,451.34
	(d) Long term loans and advances	18	6,479.49	530.34
	(e) Other non-current assets	19	2,22,026.06	2,339.05
	<b>Total Non current assets</b>		<b>8,84,450.89</b>	<b>8,69,118.94</b>
2	<b>Current Assets</b>			
	(a) Current investments		-	-
	(b) Inventories	20	1,78,541.77	88,137.54
	(c) Trade receivables	21	2,48,770.37	2,61,176.25
	(d) Cash and cash equivalent	22	6,095.19	6,465.25
	(e) Short Term loans and advances	23	2,12,104.33	1,97,692.82
	(f) Other current assets	24	-	-
	<b>Total Current Assets</b>		<b>6,45,511.65</b>	<b>5,53,471.86</b>
	<b>Total</b>		<b>15,29,962.54</b>	<b>14,22,590.80</b>

The notes on account form integral part of the financial statements 1 to 41

For RAJESH J. SHAH & ASSOCIATES

Chartered Accountants

Firm Registration No. 108407W

CA RAJESH J. SHAH  
PARTNER

Membership No : 040268

UDIN :

Place : Ahmedabad

Date : 23rd September, 2022



For, RATNATRIS PHARMACEUTICALS PVT. LTD

For and on behalf of the Board of Directors

JITENDRA B. SANGHAVI  
Director

DIN NO.: 00271995

Place : Ahmedabad

Date : 23rd September, 2022

SWAPNIL J. SHAH  
Director

DIN NO.: 05259821

# RATNATRIS PHARMACEUTICALS PRIVATE LIMITED

CIN : U24230GJ2005PTC047394

REGISTERED OFFICE ADDRESS : 1004-1006, 10th Floor, North Tower, One42, Off Bopal Ambli road, Bodakdev, Ahmedabad GJ 380054 INDIA

## Statement of Profit and Loss for the year ended March 31, 2022

Amount in ` '000


PARTICULARS	NOTE NO	As at March 31, 2022	As at March 31, 2021
I Revenue from operations	25	7,96,564.99	7,49,865.09
II Other Income	26	7,125.60	37,113.62
III Total Income (I+II)		8,03,690.59	7,86,978.71
IV Expenses			
Cost of materials consumed	27	5,12,664.48	4,71,257.44
Purchase of stock-in-trade (Finished Goods)		32,319.95	75,527.74
Changes in inventories of finished goods, Work in progress and Stock in Trade	28	2,991.24	2,771.29
Manufacturing expenses	29	1,26,166.78	1,07,420.34
Employee benefits expenses	30	93,955.85	73,561.09
Finance cost	31	45,863.88	43,820.36
Depreciation and amortization expenses	32	45,425.34	46,318.48
Other expenses	33		
a) Office and Administrative Overheads		16,826.82	10,177.29
b) Sales & Marketing Expenses		21,253.14	13,521.70
Total expenses		8,97,467.48	8,44,375.73
V Profit/(Loss) before exceptional and extraordinary items and tax (III-IV)		(93,776.90)	(57,397.03)
VI Exceptional items		-	-
VII Profit/(Loss) before extraordinary items and tax (V-VI)		(93,776.90)	(57,397.03)
VIII Extraordinary items		-	-
IX Profit/(Loss) before tax (VII-VIII)		(93,776.90)	(57,397.03)
X Tax expenses			
Current Tax		-	-
Mat credit entitlement		-	-
Deferred tax		(10,896.37)	(14,421.99)
Tax adjustment of earlier year			
XI Profit/(Loss) for the period from continuing operations (XI-X)		(82,880.52)	(42,975.04)
XII Profit/(Loss) from discontinuing operations		-	-
XIII Tax expenses of discontinuing operations		-	-
XIV Profit/(Loss) from discontinuing operations after tax		-	-
XV Profit/(Loss) for the period (XI+XIV)		(82,880.52)	(42,975.04)
XVI Earning per equity share	34		
(1) Basic		-44.16	-23.88
(2) Diluted		-44.16	-23.88

The notes on account form integral part of the financial statements 1 to 41

For RAJESH J. SHAH & ASSOCIATES

Chartered Accountants

Firm Registration No. 108407W



CA RAJESH J. SHAH

PARTNER

Membership No : 040268

UDIN :



For, RATNATRIS PHARMACEUTICALS PVT. LTD


For and on behalf of the Board of Directors



JITENDRA B. SANGHAVI

Director

DIN NO.: 00271995



SWAPNIL J. SHAH

Director

DIN NO.: 05259821





Place : Ahmedabad

Date : 23rd September, 2022

Place : Ahmedabad

Date : 23rd September, 2022



RATNATRIS PHARMACEUTICALS PRIVATE LIMITED		
CIN : U24230GJ2005PTC047394		
REGISTERED OFFICE ADDRESS : 1004-1006, 10th Floor, North Tower, One42, Off Bopal Ambli road, Bodakdev, Ahmedabad GJ 380054 INDIA		
Cash Flow Statement for the year ended March 31, 2022		
	Amount in ' '000	
Particulars	For the Year Ended 31 March, 2022	For the Year Ended 31 March, 2021
<b>1. Cash Flow From Operating Activities:</b>		
Net Profit before Taxation	(93,776.90)	(57,397.03)
Add:		
Depreciation	45,425.34	46,318.48
Interest expense	43,111.10	42,103.73
Bad debt	-	-
Loss on sale of investments	-	-
Loss on sale of assets	40.42	44.05
	<b>(5,200.03)</b>	<b>31,069.23</b>
Less:		
Dividend income	-	-
Profit on sale of assets	-	177.57
Interest income	195.47	321.22
Foreign Exchange Unrealised	2,937.14	591.72
Profit on sale of investments	-	-
	<b>3,132.62</b>	<b>1,090.51</b>
<b>Operating profit before working capital changes</b>	<b>(8,332.65)</b>	<b>29,978.72</b>
Add/Less: Changes in working capital		
Increase/(Decrease) in Trade Payables	1,37,298.23	61,590.84
(Increase)/Decrease in Inventories	(90,404.23)	3,693.11
(Increase)/Decrease in Trade Receivables	12,405.88	(1,53,660.07)
Increase/(Decrease) in Other Current Liabilities	9,414.27	(12,891.45)
(Increase)/Decrease in Other current Assets	-	32.76
(Increase)/Decrease in Long Term Provision	1,17,185.93	-
(Increase)/Decrease in Long Term loans & advances	(5,949.16)	(530.34)
(Increase)/Decrease in Short Term loans & advances	(14,411.51)	(11,773.74)
Increase/(Decrease) in Provisions	-	(11,771.34)
	<b>1,65,539.41</b>	<b>(1,25,310.22)</b>
<b>Less: Adjustment for Taxes:</b>		
Direct taxes paid	-	-
Tax adjustment of earlier year	-	-
Income tax refund	-	-
	-	-
<b>Cash generated/ (used in) from operating activities (A)</b>	<b>1,57,206.76</b>	<b>(95,331.50)</b>
<b>2. Cash Flow From Investing Activities:</b>		
Interest income	195.47	321.22
Foreign Exchange Unrealised	2,937.14	591.72
Proceeds from sale of investments	-	-
Purchase of investments	(3.40)	(6.85)
Deposits Redemption/(placed)	(2,19,687.01)	1,828.10
Proceeds from Sale of fixed assets	11.72	476.00
Dividend income	-	-
Purchase of fixed assets	(3,566.42)	(2,781.84)
	<b>(2,20,112.50)</b>	<b>428.35</b>
<b>Net cash generated/ (used in) from Investing Activities (B)</b>	<b>(2,20,112.50)</b>	<b>428.35</b>
<b>3. Cash Flow From Financing Activities:</b>		
Proceeds from long term borrowings	(4,68,807.10)	1,39,645.60
Repayment of long term borrowings	-	-
Proceeds from short term borrowings	(51,307.65)	(2,222.49)
Repayment of short term borrowings	-	-
Increase / (Decrease) in Share Capital due to Compromised and Arrangement Scheme	766.36	-
Increase / (Decrease) in Security Premium / Other reserve due to Compromised and Arrangement Scheme	14,477.87	-
Increase / (Decrease) in Loss due to Compromised and Arrangement Scheme	4,31,224.36	-
Increase / (Decrease) in Fixed Assets due to Compromised and Arrangement Scheme	1,06,889.39	-
Increase / (Decrease) in Deferred Tax Assets due to Compromised and Arrangement Scheme	72,403.55	-
Interest paid	(43,111.10)	(42,103.73)
Dividend paid	-	-
	<b>62,535.67</b>	<b>95,319.39</b>
<b>Net cash generated/ (used in) from financing activities (C)</b>	<b>62,535.67</b>	<b>95,319.39</b>
Net increase or decrease in Cash and Cash Equivalents (A+B+C)	(370.06)	416.23
Opening cash and cash equivalents	6,465.25	6,049.02
<b>Closing cash and cash equivalents</b>	<b>6,095.19</b>	<b>6,465.25</b>
<b>Notes</b>		
1. Statement of Cash Flow has been prepared under the indirect method as set out in AS 3 on "Statement of Cash Flows" specified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014.		
2. Reconciliation of Cash and Cash Equivalents as per the Statement of Cash Flow.		
Particulars	As At 31-Mar-22	As at 31-Mar-21
Balances with Banks		
In Current accounts	868.92	1,490.67
In Overdraft account (debit balance)	-	-
In Fixed deposits (original maturity of 3 months or less)	-	-
In Fixed deposits (original maturity of 3 months or more)	5,017.64	4,846.14
Cash on hand	208.62	128.44
Cheques, drafts on hand	-	-
Others - Unpaid dividend Account	-	-
<b>Cash and cash equivalents as at the end of the year (Refer Note 23)</b>	<b>6,095.19</b>	<b>6,465.25</b>
The notes on account form integral part of the financial statements 1 to 41		
As per our report of even date		
For RAJESH J. SHAH & ASSOCIATES Chartered Accountants Firm Registration No. 108407W		
 		
CA RAJESH J. SHAH PARTNER Membership No : 040268 UDIN :		
Place : Ahmedabad Date : 23rd September, 2022		
For, RATNATRIS PHARMACEUTICALS PVT. LTD For and on behalf of the Board of Directors  		
JITENDRA B. SANGHAVI Director DIN NO.: 00271995		
SWAPNIL J. SHAH Director DIN NO.: 05259821		
Place : Ahmedabad Date : 23rd September, 2022		

## RATNAMANI HEALTHCARE PRIVATE LIMITED

### Notes forming part of the Financial Statements and Significant Accounting Policies

#### 1) Corporate Information

1. The Company was incorporated on 29<sup>th</sup> December, 2005 in the name of Intelligence Pharmaceuticals Pvt. Ltd. It purchased the manufacturing unit situated at Survey No. 416 (old S. No. 750/1), Ahmedabad - Mehsana Highway, Nr. Chhatral GIDC, Taluka - Kadi, Dist. - Mehsana, Pin - 382715. The Name of the company has been changed from Intelligence Pharmaceuticals Pvt. Ltd to Ratnamani Healthcare Pvt. Ltd. as on 23/03/2010. The Corporate Identity Number (CIN) of the company is U24230GJ2005PTC047394

2. The company carried out manufacturing of tablets, oral-liquid, capsules, powders, Injections and supplies mainly to Local and foreign customers.

3. Ratnatris Pharmaceuticals Pvt Ltd (formally known as Ratnamani Healthcare Private Limited) is amongst fastest emerging companies with focus on pharmaceutical formulations. Ratnamani is having state of the art manufacturing facility which manufactures Tablets/Capsules/Syrup, Dry Powder Syrup, Injections and effervescent tablets/powder. The company offers fresh approach and perspective to the global pharmaceutical industry by supplying a comprehensive basket of pharmaceutical drugs in various therapeutic segments and OTC preparations.

#### 2) Summary of Significant Accounting Policies

##### a) Use of Estimates

The preparation of the financial statements in conformity with Indian GAAP requires the Management to make estimates and assumptions considered in the reported amounts of assets and liabilities (including contingent liabilities) and the reported income and expenses during the year. The Management believes that the estimates used in preparation of the financial statements are prudent and reasonable. Future results could differ due to these estimates and the differences between the actual results and the estimates are recognised in the periods in which the results are known / materialise.

##### b) Recognition of Income & Expenditure

1. The financial statements have been prepared under the historical cost convention, in accordance with the generally accepted accounting principles and provision of the Companies Act, 2013.

2. The Company generally follows mercantile system of accounting and recognizes significant items of Income and expenditure on accrual basis.

##### c) Inventories

Inventories of Raw Materials, Packing Materials and Work in progress are valued at cost; Finished Goods is valued at Cost or Market value whichever is lower. The value of inventory has been made excluding the Goods & Service Tax

##### d) Fixed Assets

###### Tangible Assets

Fixed Assets are stated at cost less accumulated depreciation less impairment losses, if any. Cost comprises the purchase price or acquisition cost and any attributable cost of bringing the assets to working condition for its intended use.

Subsequent expenditures related to an item of Tangible Asset are added to its book value only if they increase the future benefits from the existing asset beyond its previously assessed standard of performance.

###### Intangible Assets

Intangible Assets are stated at cost of acquisition net of recoverable taxes less accumulated amortisation/depletion and impairment loss, if any. The cost comprises purchase price, borrowing costs, and any cost directly attributable to the intended use and net charges on foreign exchange contracts and adjustments arising from exchange rate variations attributable to the intangible assets.

##### e) Depreciation, Amortisation and Depletion

1) Depreciation is provided based on useful life of the assets as prescribed in Schedule II to the Companies Act, 2013

##### f) Employee Benefits

The company has created provision for Gratuity & Leave Encashment accrued during the financial year.

##### g) Inflation

The assets and liabilities are recorded at historical cost in the company. These costs are not adjusted to reflect the changing value in the purchasing power of money.

##### h) Revenue Recognition

###### Sale of Goods

Sales are recognised, net of returns and trade discounts, as and when the goods are removed and despatched to the customers. Sales exclude Goods & Service Tax deducted from Revenue (Gross).

###### Interest Income

Interest Income is recognised on a time proportion basis. Interest Income is included under the head "Other Income" in the statement of profit and loss.

###### Goods & service tax

Goods & Service Tax is accounted on the basis of both, payments made in respect of goods cleared / services provided.

##### i) Foreign Currency Transaction

a. Transactions denominated in foreign currencies are recorded at the exchange rate prevailing on the date of the transaction or that approximates the actual rate at the date of the transaction.

b. Monetary items denominated in foreign currencies at the year end are restated at year end rates.

c. Any income or expense on account of exchange difference either on settlement or on translation is recognised in the Profit and Loss Statement.

##### k) Income Taxes

Tax expense comprises of current tax and deferred tax. Current tax is measured at the amount expected to be paid to the tax authorities, using the applicable tax rates. Deferred income tax reflect the current period timing differences between taxable income and accounting income for the period and reversal of timing differences of earlier years/period. Deferred tax assets are recognised only to the extent that there is a reasonable certainty that sufficient future income will be available except that deferred tax assets, in case there are unabsorbed depreciation or losses, are recognised if there is virtual certainty that sufficient future taxable income will be available to realise the same.

Deferred tax assets and liabilities are measured using the tax rates and tax law that have been enacted or substantively enacted by the Balance Sheet date.

##### l) Provisions, Contingent liabilities and Contingent Assets

Provision is recognised in the accounts when there is a present obligation as a result of past event(s) and it is probable that an outflow of resources will be required to settle the obligation and a reliable estimate can be made.

Contingent liabilities are disclosed unless the possibility of outflow of resources is remote.  
Contingent assets are neither recognised nor disclosed in the financial statements.





**RATNATRIS PHARMACEUTICALS PRIVATE LIMITED**

CIN : U24230GJ2005PTC047394

 REGISTERED OFFICE ADDRESS : 1004-1006, 10th Floor, North Tower, One42, Off Bopal Ambli road, Bodakdev, Ahmedabad GJ 380054  
INDIA

**Notes forming part of the Financial Statement for the year March 31, 2022**
**NOTE : 3 Share Capital**

Amount in ₹ '000

Particulars	As at March 31, 2022	As at March 31, 2021
Authorised		
45,00,000 Equity Shares of Rs 10/- Each	45,000.00	18,000.00
Issued, Subscribed & Paid up		
18,76,636 Equity Shares of Rs. 10/- each fully paid up	18,766.36	18,000.00
(Previous Year - 18,00,000 Equity Shares of Rs. 10/- each fully paid up)		
<b>TOTAL Rs.</b>	<b>18,766.36</b>	<b>18,000.00</b>

**Terms/Rights attached to Equity Shares**

The Company has single class of equity shares having par value of Rs 10/- per share. Accordingly, all equity shares rank equally with regard to dividends and share in the Company's residual assets. The equity shares are entitled to receive dividend declared from time to time.

**Reconciliation of the shares outstanding at the beginning and at the end of the reporting period**

Amount in ₹ '000

Particulars	As at March 31, 2022		As at March 31, 2021	
	No. of shares	Amount Rs.	No. of shares	Amount Rs.
At the beginning of the period	1,800.00	18,000.00	1,800.00	18,000.00
Add: New issue during the period (Pending allotment as per order of Honourable NCLT dtd. 20/09/2022)	256.64	2,566.36	-	-
Less : Reduction in Capital due to Compromised and Arrangement Scheme applied to Honorable NCLT & as per order passed by Honorable NCLT dt. 20/09/22 (see Note No. 40 (f) )	180.00	1,800.00	-	-
<b>Outstanding at the end of period</b>	<b>1,876.64</b>	<b>18,766.36</b>	<b>1,800.00</b>	<b>18,000.00</b>

**Details of shareholders holding more than 5% shares in the Company**

Amount in ₹

Name of the Shareholders	Percentage Holding As at		No. of Shares As at	
	March 31, 2022	March 31, 2021	March 31, 2022	March 31, 2021
Ratnamani Marketing Pvt Ltd	39.97%	46.30%	750,000.00	833,333.00
Jitendra Babulal Sanghvi	13.33%	10.37%	250,091.00	186,667.00
Jayanti Misrimal Sanghvi	8.63%	10.00%	162,000.00	180,000.00
Dimple Manoj Sanghvi	5.75%	6.67%	108,000.00	120,000.00
Manoj Prakash Sanghvi	5.75%	6.67%	108,000.00	120,000.00
Pavan Misrimal Sanghvi	5.75%	6.67%	108,000.00	120,000.00
Vimla Pavan Sanghvi	5.75%	6.67%	108,000.00	120,000.00
Kaushal Champalal Bhansali	6.76%	0.00%	126,818.00	-
<b>Total</b>	<b>91.70%</b>	<b>93.33%</b>	<b>1,720,909.00</b>	<b>1,680,000.00</b>

As per the records of the Company, including its register of shareholders/members and other declarations received from the shareholders regarding beneficial interest, the above shareholding represents both legal and beneficial ownership of shares.

**Shares held by promoters at the end of the year**

Promoters' Names	As at March 31, 2022		As at March 31, 2021		% Changes
	No. of Shares	% of total shares	No. of Shares	% of total shares	
Ratnamani Marketing Pvt Ltd	750,000.00	39.97%	833,333.00	46.30%	-6.33%
Jitendra Babulal Sanghvi *	250,091.00	13.33%	186,667.00	10.37%	2.96%
Jayanti Misrimal Sanghvi	162,000.00	8.63%	180,000.00	10.00%	-1.37%
Dimple Manoj Sanghvi	108,000.00	5.75%	120,000.00	6.67%	-0.91%
Manoj Prakash Sanghvi	108,000.00	5.75%	120,000.00	6.67%	-0.91%
Pavan Misrimal Sanghvi	108,000.00	5.75%	120,000.00	6.67%	-0.91%
Vimla Pavan Sanghvi	108,000.00	5.75%	120,000.00	6.67%	-0.91%
Shanti Mishrimal Sanghvi	54,000.00	2.88%	60,000.00	3.33%	-0.46%
Sashi Shantilal Sanghvi	54,000.00	2.88%	60,000.00	3.33%	-0.46%
<b>Total</b>	<b>1,702,091.00</b>	<b>90.70%</b>	<b>1,800,000.00</b>	<b>100.00%</b>	<b>-0.09</b>

There were no instances of shares being issued/allotted by way of bonus shares or for consideration other than cash and no shares have been bought back by the company during the period of five years immediately preceding the date of balance sheet.

\* Out of 2,50,091 equity shares, pending allotment of 82,091 equity shares as per the order passed by the Hon'ble NCLT dtd 20/09/2022.

NOTE : 4 Reserves and surplus		Amount in ` '000	
Particulars	As at March 31, 2022	As at March 31, 2021	
<b>a) Securities premium</b>			
Opening Balance	1,79,900.00	1,79,900.00	
<b>Add:</b> Receipt on issue of equity shares allotment due to Compromised and Arrangement Scheme applied to Honorable NCLT & as per order passed by Honorable NCLT dt. 20/09/22 (see Note No. 40 (f) )	25,663.64	-	
Less: 10 % Reduction due to Compromised and Arrangement Scheme applied to Honorable NCLT & as per order passed by Honorable NCLT dt. 20/09/22 (see Note No. 40 (f) )	17,990.00	-	
<b>Closing Balance</b>	<b>1,87,573.64</b>	<b>1,79,900.00</b>	
<b>b) Capital Reserve Fund</b>	<b>6,804.24</b>	<b>-</b>	
as per Note NO. 40(f) mentioned herein below.			
<b>b) Surplus</b>			
Opening Balance	(4,31,224.36)	(3,88,249.32)	
<b>Add:</b> Profit / (Loss) transferred from Statement of Profit and Loss	(82,880.52)	(42,975.04)	
Less: Adjustment relating to Fixed Assets (refer Note No. 8)	-	-	
Less: Reduction Loss due to Compromised and Arrangement Scheme applied to Honorable NCLT & as per order passed by Honorable NCLT dt. 20/09/22 (see Note No. 40 (f) )	(4,31,224.36)	-	
Less: used toward Buy Back of Equity Shares	-	-	
<b>Closing Balance</b>	<b>(82,880.52)</b>	<b>(4,31,224.36)</b>	
<b>TOTAL Rs.</b>	<b>1,11,497.35</b>	<b>(2,51,324.36)</b>	





NOTE : 5 Long-term borrowings		Amount in ` '000	
Particulars	As at March 31, 2022	As at March 31, 2021	
<b>Secured Loans</b>			
<b>Term Loans from Bank - Secured:</b>			
1. HDFC Bank Ltd - Term Loan (The above loan carries interest @ 8.25% p.a. The loan is repayable in 60 monthly installments of Rs. 402584 lacs including interest starting from April - 2024.)	12,800.00	-	
2. HDFC Bank Ltd - WCTL (The above loan carries interest @ 8.25% p.a. The loan is repayable in 48 monthly installments of Rs. 810491 lacs including interest starting from July - 2021.)	11,641.04	19,910.05	
<b>Total Rs.</b>	<b>24,441.04</b>	<b>19,910.05</b>	
<b>Unsecured</b>			
<b>Bond / Debentures</b>			
<b>0% Unsecured fully Compulsory Convertible Debentures (CCDs) Series - 1</b>	69,498.00	-	
6,31,800 Zero 0% Unsecured fully Compulsory Convertible Debentures (CCDs) Series - 1 (Face Value of Rs. 110/- each			
<b>Zero Coupon Non- Convertible Debentures (NCDs)</b>	2,20,000.00	-	
1. Zero Coupon NCDs will not carry any Interest and they will unsecured			
2. The redemption Zero Coupon NCDs is linked to the recovery of the items of assets, which are categorised as Non-Current Assets			
3. As and when the company makes recovery / realisation of any Non-Current Assets, the Zero Coupon NCDs will be redeemed progressively by the company.			
4. If the Company has not recovered any Non-Current Assets within 15 fiscal year, then any unrecovered amount of Non-current Assets will be writeoff by the company against the written back in capital reserve fund, there after nothing will payable to Zero Coupon NCDs holders			
5. As per Compromised and Arrangement Scheme applied to Honorable NCLT & as per order passed by Honorable NCLT dt. 20/09/22 (see Note No. 40 (f) )			
<b>Other loans and advances (specify nature)</b>			
a) Loans from Directors	47,510.00	7,10,600.00	
b) Loans from Related Parties	-	-	
c) Loans from Corporate	4,74,966.99	5,74,713.07	
<b>TOTAL Rs.</b>	<b>8,36,416.03</b>	<b>13,05,223.13</b>	

**\* Nature of Security**

(a) Primarily secured by hypothecation by way of first and exclusive charge in all present and future stocks and book debts, and hypothecation by way of first and exclusive charge in all plant and machinery. Further, collaterally secured by Equitable Mortgage of 100 % share of NA land admeasuring about 35205 Sq. Mtr bearing amalgamated Revenue Survey No. 416 (old S. NO. 750/1) situated, laying & being at Mouje Village Indrad, Taluka KADI and Equitable Mortgage of Factory building thereon.

(b) personal guarantee of Share holders more than 75 % and Collateral Security of owners, FD as cash margin for BG/LC, LC for FBD and Drul, Stock for Exports, Exports Debtors / FBD DISC.

(c) Secured against Hypothecation of Plant & Machinery, Stock viz RM, WIP, FG, Packing Material, Book Debt, Bills, Money Deposits. Further, secured by hypothecation of goods received under LC and receivable arising from sale proceeds thereof.

(d) Collaterally secured by Equitable Mortgage of 100 % share of NA land admeasuring about 35205 Sq. Mtr bearing amalgamated

(e) personal guarantee of Share holders more than 75 % and Collateral Security of owners, FD as cash margin for BG/LC, LC for FBD and Drul, Stock for Exports, Exports Debtors / FBD DISC.

**The CCDs will be issued on following Terms**

a) The CCDs shall be unsecured and unlisted and compulsorily converted into Equity Shares. Conversion into shares will be within 12 months from the date of allotment, in one or more tranches, at the discretion of the Company.

b) The CCDs shall be converted into Equity Shares of face value of Rs. 10/- each at a price as may be decided later on based of the valuation report.(Conversion Price). If, at the time of conversion of such CCDs into Equity shares, any fraction balance remains, for whatever reasons, the said amount shall be refunded to the respective CCD holder.

c) The CCDs by themselves do not give any right of voting in the Company.

d) The new Equity Shares issued on conversion of CCDs shall be in physical form and subject to the Memorandum and Articles of Association of the Company and after conversion into Equity Shares, they shall rank pari-passu in all respects with the existing issued and subscribed Equity Shares of the Company.

e) Rate of Interest or Coupon is 0 % p.a.

f) The CCDs are transferable, subject to approval of the Board of Directors of the Company.

**Note : Company is not declared wilful defaulter by any bank or financial institutions or other lenders.**

**NOTE : 5.1 Registration of charges or satisfaction with Registrar of Companies**

Particular of charge	Statutory period of registration	Actual date of registration	Reason if Charge date of is registered registration beyond statutory period
(The Company has registered all charges or satisfaction with Registrar of Companies within the statutory period)			



NOTE : 6 Other long-term liabilities		Amount in ` '000	
Particulars	As at March 31, 2022	As at March 31, 2021	
<b>Trade Payables * Outstanding more than one years</b>			
From Related Parties	-	-	
From Others	2,033.75	2,033.75	
Others (PF, ESIC, Professional Tax, LWF)	10,047.90	10,038.22	
<b>TOTAL Rs.</b>	<b>12,081.65</b>	<b>12,071.97</b>	

*Trade Payables ageing schedule		Amount in ` '000					
Particulars	As at March 31, 2022						
	Outstanding for following periods from due date of payment						
	Not due for payment	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total	
(i) MSME	-	-	-	-	-	-	
(ii) Others	-	-	-	-	2,033.75	2,033.75	
(iii) Disputed dues MSME	-	-	-	-	-	-	
(iv) Disputed dues Others	-	-	-	-	-	-	
<b>TOTAL Rs.</b>						<b>2,033.75</b>	

*Trade Payables ageing schedule		Amount in ` '000					
Particulars	As at March 31, 2021						
	Outstanding for following periods from due date of payment						
	Not due for payment	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total	
(i) MSME	-	-	-	-	-	-	
(ii) Others	-	-	-	-	2,033.75	2,033.75	
(iii) Disputed dues MSME	-	-	-	-	-	-	
(iv) Disputed dues Others	-	-	-	-	-	-	
<b>TOTAL Rs.</b>						<b>2,033.75</b>	

NOTE : 7 Long term provisions		Amount in ` '000	
Particulars	As at March 31, 2022	As at March 31, 2021	
Provision for employee benefits	-	-	
Others Long Term Liability (due to Compromised and Arrangement Scheme applied to Honorable NCLT & as per order passed by Honorable NCLT dt. 20/09/22 (see Note No. 40 (f) )	1,17,185.93	-	
<b>TOTAL Rs.</b>	<b>1,17,185.93</b>	<b>-</b>	

NOTE : 8 Short term borrowings		Amount in ` '000	
Particulars	As at March 31, 2022	As at March 31, 2021	
<b>Loans repayable on demand</b>			
<b>Working capital loans from bank - Secured:</b>			
HDFC Bank Cash Credit	70,714.17	1,21,624.88	
(Secured against exclusive 1st charge by way of Hypothecation of entire Raw Materials, Stock-in-process, stores & spares, packing materials, finished goods and book-debts of the Company, both present & Future. and personal guarantee of Directors and other Primary and Collateral Security as mentioned in Note 5.)			
The same is repayable on demand and carries interest @ 8.75%)			
<b>Loans and advances from related parties (Unsecured)</b>			
From Directors	-	-	
From Relatives	-	-	
Deposits	-	-	
Other loans & advances	-	-	
<b>Current maturities of Long Term Borrowings</b>			
HDFC Bank Ltd- WCTL (MORATORIUM TERM LOAN)	8,269.01	2,806.73	
HDFC Bank Ltd- WCTL (NEW T.L. AG.NO. 452529491)	-	5,859.23	
<b>TOTAL Rs.</b>	<b>78,983.19</b>	<b>1,30,290.84</b>	





NOTE : 9 Trade Payables

Particulars	As at March 31, 2022	As at March 31, 2021
Trade Payables *		
Dues to MSMED Creditors#	74,245.86	28,843.79
Creditor For Goods & Packing Materials		
From Related Parties	52,557.96	22,512.98
From Others	1,85,021.35	1,26,886.86
Creditor For Expenses		
From Related Parties	-	-
From Others	15,491.69	12,744.52
Creditor For Capital Goods		
From Related Parties	-	-
From Others	1,839.20	879.37
TOTAL Rs.	3,29,156.07	1,91,867.52

#Note for MSMED

The Company has received the information and certificate of Registration under MSMED from its Supplier and hence, the details has been disclosed here as per MSME-1 Form filed by company.

\*Trade Payables ageing schedule

Amount in ` '000

Particulars	As at March 31, 2022					
	Outstanding for following periods from due date of payment					
	Not due for payment	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	34,531.12	39,714.74	-	-	-	74,245.86
(ii) Others	2,15,565.93	37,176.44	905.74	-	1,262.10	2,54,910.20
(iii) Disputed dues MSME						-
(iv) Disputed dues Others						-
TOTAL Rs.						3,29,156.07

\*Trade Payables ageing schedule

Amount in ` '000

Particulars	As at March 31, 2021					
	Outstanding for following periods from due date of payment					
	Not due for payment	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	25,488.24	3,355.55	-	-	-	28,843.79
(ii) Others	1,19,871.26	41,174.98	57.49	764.11	1,155.89	1,63,023.73
(iii) Disputed dues MSME						-
(iv) Disputed dues Others						-
TOTAL Rs.						1,91,867.52

Note 10 Other current liabilities

Amount in ` '000

Particulars	As at March 31, 2022	As at March 31, 2021
Current maturities of finance lease obligations	-	-
Interest accrued but not due on borrowings	181.36	162.40
Interest accrued and due on borrowings	-	-
Income received in advance	-	-
Unpaid dividends	-	-
Share application money due for refund and interest accrued thereon	-	-
Unpaid matured deposits and interest accrued thereon	-	-
Unpaid matured debentures and interest accrued thereon	-	-
Duties & Taxes Payable	-	-
TDS & TCS Payable	4,053.29	2,528.41
GST RCM Payable	247.75	30.79
Advances from customers	13,137.79	7,707.11
Unpaid expense	8,255.79	6,032.99
TOTAL Rs.	25,875.97	16,461.70

NOTE : 11 Short term provisions

Amount in ` '000

Particulars	As at March 31, 2022	As at March 31, 2021
Income Tax Payable	-	-
Provision for Employee Benefits	-	-
TOTAL Rs.	-	-



Note 12 Property, Plant & Equipments										
Name of the Asset	Gross Carrying Amount				Depreciation/ Impairment			Net Carrying Amount		As at March 31,2021
	As at April 01, 2021	Additions	Disposals	Reduction due to Compromised and Arrangement Scheme	Amount of change due to revaluation	Total	As at April 01, 2021	On Addition	Impairment losses/reversals	Total
<b>Indrad Unit</b>										
Factory Land	12,396.00	-	-	-	-	12,396.00	-	-	-	12,396.00
Factory Building	2,62,814.93	-	-	-	-	2,62,814.93	32,736.73	8,457.09	-	41,193.82
Air Conditioner-AHU Plant	1,21,810.14	106.20	-	-	-	1,21,916.34	21,308.38	5,787.96	-	27,096.34
Air Conditioner	98.13	-	-	-	-	98.13	24.05	4.66	-	28.71
Borewell- Indrad unit	1,445.73	-	-	-	-	1,445.73	1,373.45	-	-	1,373.45
Computer & Printers	4,298.26	1,130.28	-	-	-	5,428.54	3,398.29	523.88	-	3,922.16
Electrical Installation	56,573.22	41.55	-	-	-	56,614.77	20,371.40	5,157.24	-	25,528.65
ETP Plant	3,534.78	-	-	-	-	3,534.78	1,029.53	167.90	-	1,197.43
Furniture & Fixtures	32,047.83	-	-	-	-	32,047.83	13,035.82	2,823.62	-	15,859.44
Laboratory Equipments	49,168.90	33.00	-	-	-	49,201.90	21,230.40	4,415.36	-	25,645.77
Lift	290.81	-	-	-	-	290.81	205.08	14.44	-	219.52
Office Equipments	4,176.75	97.50	-	-	-	4,274.25	2,925.20	535.76	-	3,460.96
Other Asset	8,965.50	101.80	-	-	-	9,067.30	2,015.40	427.32	-	2,442.71
Pharma Lib	75.39	-	-	-	-	75.39	37.01	3.58	-	40.60
Plant & Machinery	3,15,921.80	2,038.06	-	1,06,889.39	-	2,11,070.47	58,962.06	14,964.79	-	73,926.85
Motor Vehicle	5,711.45	18.04	1,042.82	-	-	4,686.67	3,410.17	554.40	990.68	2,973.90
Wind Mill	34,500.00	-	-	-	-	34,500.00	11,286.88	1,481.94	-	12,768.82
<b>Total (A)</b>	<b>9,13,829.62</b>	<b>3,566.42</b>	<b>1,042.82</b>	<b>1,06,889.39</b>	<b>-</b>	<b>8,09,463.84</b>	<b>1,93,349.83</b>	<b>45,319.94</b>	<b>990.68</b>	<b>2,37,679.10</b>
<b>Corporate Office Unit</b>										
Building	-	-	-	-	-	-	-	-	-	-
Computer	-	-	-	-	-	-	-	-	-	-
Electrification	-	-	-	-	-	-	-	-	-	-
Furniture & Fixtures	-	-	-	-	-	-	-	-	-	-
Office Equipment	-	-	-	-	-	-	-	-	-	-
<b>Total (B)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Total (A+B)</b>	<b>9,13,829.62</b>	<b>3,566.42</b>	<b>1,042.82</b>	<b>1,06,889.39</b>	<b>-</b>	<b>8,09,463.84</b>	<b>1,93,349.83</b>	<b>45,319.94</b>	<b>990.68</b>	<b>2,37,679.10</b>
<b>Total of previous year</b>	<b>9,12,721.65</b>	<b>2,781.84</b>	<b>741.80</b>			<b>9,14,761.69</b>	<b>1,48,105.16</b>	<b>46,318.48</b>	<b>399.32</b>	<b>1,94,024.32</b>
										<b>7,20,479.79</b>
										<b>7,64,616.49</b>

Note 13										
Intangible Assets	932.07	-	-	-	-	932.07	674.48	105.40	-	779.89
										152.18
<b>Total</b>	<b>932.07</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>932.07</b>	<b>674.48</b>	<b>105.40</b>	<b>-</b>	<b>779.89</b>
<b>Total of previous year</b>	<b>751.77</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>751.77</b>	<b>534.45</b>	<b>95.21</b>	<b>-</b>	<b>629.66</b>
										<b>122.11</b>
										<b>257.59</b>
										<b>257.59</b>
										<b>217.32</b>





**Note 14 Capital-work-in progress** **Amount in ` '000**  
**Ageing schedule**

**As at March 31, 2022**

	Amount in CWIP for a period of				
<b>CWIP</b>	<b>Less than 1 year</b>	<b>1-2 years</b>	<b>2-3 years</b>	<b>More than 3 years</b>	<b>Total</b>
Projects in progress	-	-	-	-	-
Projects temporarily suspended	-	-	-	-	-
<b>Total</b>	-	-	-	-	-

**As at March 31, 2021**

	Amount in CWIP for a period of				
<b>CWIP</b>	<b>Less than 1 year</b>	<b>1-2 years</b>	<b>2-3 years</b>	<b>More than 3 years</b>	<b>Total</b>
Projects in progress	-	-	-	-	-
Projects temporarily suspended	-	-	-	-	-
<b>Total</b>	-	-	-	-	-

<b>Note 16</b>	<b>As at March 31, 2022</b>	<b>As at March 31, 2021</b>
<b>Non-current investments</b>		
<b>Other non-current investments</b>		
Investment in Government Securities (Unquoted)		
National Savings Certificate	1.00	1.00
Investment in Other than Government Securities (Unquoted)		
Silver Coins	63.24	59.85
<b>Total</b>	<b>64.24</b>	<b>60.85</b>



NOTE : 17 Deferred tax		Amount in ` '000	
Particulars	As at March 31, 2022		
	Opening Balance	Recognised in Profit & loss	Closing Balance
a. Deferred Tax Assets			
Unabsorbed Depreciation	99,991.47	16,898.48	1,16,889.95
Unabsorbed Loss	99,345.57	10,168.74	1,09,514.31
Unpaid Bonus/Leave Enc/ Gratuity	1,877.20	(164.84)	1,712.36
Reduction due to Compromised and Arrangement Scheme applied to Honorable NCLT & as per order passed by Honorable NCLT dt. 20/09/22 (see Note No. 40 (f) )	-	-	(72,403.55)
Total Deferred Tax Assets	2,01,214.24	26,902.38	1,55,713.07
b. Deferred Tax Liabilities			
Property, Plant and Equipment and Intangible Assets	(55,762.90)	(16,006.00)	(71,768.90)
Total Deferred Tax Liabilities	(55,762.90)	(16,006.00)	(71,768.90)
Deferred Tax Asset (Liabilities) Net	1,45,451.34	10,896.37	83,944.16
Amount in ` '000			
Particulars	As at March 31, 2021		
	Opening Balance	Recognised in Profit & loss	Closing Balance
a. Deferred Tax Assets			
Unabsorbed Depreciation	80,596.45	19,395.03	99,991.47
Unabsorbed Loss	98,455.38	890.19	99,345.57
Unpaid Bonus/Leave Enc/ Gratuity	477.25	1,399.95	1,877.20
Total Deferred Tax Assets	1,79,529.07	21,685.17	2,01,214.24
b. Deferred Tax Liabilities			
Property, Plant and Equipment and Intangible Assets	(48,499.72)	(7,263.18)	(55,762.90)
Total Deferred Tax Liabilities	(48,499.72)	(7,263.18)	(55,762.90)
Deferred Tax Asset (Liabilities) Net	1,31,029.35	14,421.99	1,45,451.34
NOTE : 18 Long term loans and advances			
		Amount in ` '000	
Particulars	As at March 31, 2022	As at March 31, 2021	
(Secured Considered Good):			
Capital Advances	6,479.49	530.34	
Loans and Advances to related parties	-	-	
Other Loans and Advances	-	-	
(Unsecured Considered Good):			
Capital Advances	-	-	
Loans and Advances to related parties	-	-	
Other Loans and Advances	-	-	
(Doubtful)			
Capital Advances	-	-	
Loans and Advances to related parties	-	-	
Other Loans and Advances	-	-	
Less: Provisions for doubtful advances	-	-	
TOTAL Rs.	6,479.49	530.34	





NOTE : 19 Other non current assets		Amount in ` '000	
Particulars	As at March 31, 2022	As at March 31, 2021	
(Unsecured considered good)			
Long Term Trade Receivables *	-	-	
Security Deposit	1,849.68	2,033.29	
Interest accrued but not received	23.44	154.82	
Fixed deposits having maturity of more than 12 months Others (Specify Nature)	152.94	150.94	
<b>Other Non Current Assets due to Compromised and Arrangement Scheme applied to Honorable NCLT &amp; as per order passed by Honorable NCLT dt. 20/09/22 (see Note No. 40 (f) )</b>			
GST Receivable	1,07,185.93	-	
Old Debtors Receivable	40,410.52	-	
Deferred Tax Assets written off	72,403.55	-	
<b>TOTAL Rs.</b>	<b>2,22,026.06</b>	<b>2,339.05</b>	

**Trade Receivables ageing schedule \***

		Amount in ` '000						
		As at March 31, 2022						
		Outstanding for following periods from due date of payment						
Particulars		Not due for payment	Unbilled	Less than 6 months	6 months - 1 year	1-2 year	2-3 year	More than 3 year
(i) Undisputed Trade Receivable-considered good		-	-	-	-	-	-	-
(ii) Undisputed Trade Receivable-considered doubtful		-	-	-	-	-	-	-
(iii) Disputed Trade Receivable-considered good		-	-	-	-	-	-	-
(iv) Disputed Trade Receivable-considered doubtful		-	-	-	-	-	-	-
<b>Total</b>		-	-	-	-	-	-	-

		Amount in ` '000						
		As at March 31, 2021						
		Outstanding for following periods from due date of payment						
Particulars		Not due for payment	Unbilled	Less than 6 months	6 months - 1 year	1-2 year	2-3 year	More than 3 year
(i) Undisputed Trade Receivable-considered good		-	-	-	-	-	-	-
(ii) Undisputed Trade Receivable-considered doubtful		-	-	-	-	-	-	-
(iii) Disputed Trade Receivable-considered good		-	-	-	-	-	-	-
(iv) Disputed Trade Receivable-considered doubtful		-	-	-	-	-	-	-
<b>Total</b>		-	-	-	-	-	-	-

NOTE : 20 Inventories		Amount in ` '000	
Particulars	As at March 31, 2022	As at March 31, 2021	
Raw Materials	73,891.10	44,300.47	
Packing Material	28,150.42	21,530.31	
Work-in-progress	11,018.85	11,473.39	
Finished Good	6,966.71	9,503.41	
Goods-in-Transit ( Raw Material & Packing Material)	58,514.68	1,329.95	
<b>TOTAL</b>	<b>1,78,541.77</b>	<b>88,137.54</b>	

**Note:**

Finished goods comprise of all finished goods other than those acquired for trading purposes.



NOTE : 21 Trade receivables									Amount in ` '000	
Particulars									As at March 31, 2022	As at March 31, 2021
Secured, considered good										
Unsecured, considered good										
From Related parties									24,803.93	73,245.90
From Others									2,23,966.44	1,87,930.35
Doubtful										
Less : Provisions for doubtful trade receivables									-	-
TOTAL									2,48,770.37	2,61,176.25
Trade Receivables ageing schedule *										
Amount in ` '000										
Particulars		As at March 31, 2022								
		Outstanding for following periods from due date of payment								
		Not due for payment	Unbilled	Less than 6 months	6 months - 1 year	1-2 year	2-3 year	More than 3 year	Total	
(i)	Undisputed Trade Receivable-considered good	1,95,091.16	-	5,320.49	38,057.18	3,950.49	6,351.05	-	2,48,770.37	
(ii)	Undisputed Trade Receivable-considered doubtful	-	-	-	-	-	-	-	-	
(iii)	Disputed Trade Receivable-considered good	-	-	-	-	-	-	-	-	
(iv)	Disputed Trade Receivable-considered doubtful	-	-	-	-	-	-	-	-	
Total		1,95,091.16	-	5,320.49	38,057.18	3,950.49	6,351.05	-	2,48,770.37	
Amount in ` '000										
Particulars		As at March 31, 2021								
		Outstanding for following periods from due date of payment								
		Not due for payment	Unbilled	Less than 6 months	6 months - 1 year	1-2 year	2-3 year	More than 3 year	Total	
(i)	Undisputed Trade Receivable-considered good	1,90,960.13	-	17,517.90	7,653.91	21,441.16	10,416.07	8,982.51	2,56,971.68	
(ii)	Undisputed Trade Receivable-considered doubtful								-	
(iii)	Disputed Trade Receivable-considered good	-		-	-	2,360.39	1,353.80	490.39	4,204.57	
(iv)	Disputed Trade Receivable-considered doubtful								-	
Total		1,90,960.13	-	17,517.90	7,653.91	23,801.55	11,769.86	9,472.91	2,61,176.25	





NOTE : 22 Cash & cash equivalents		Amount in ` '000	
Particulars	As at March 31, 2022	As at March 31, 2021	
Balances with banks			
<b>In Current Account</b>			
Union Bank of India-372001010036685	-	19.59	
Union Bank of India-372005070000103	59.86	259.78	
HDFC Bank Ltd - Current A/c	-	1,170.99	
IDBI Bank Ltd	-	40.32	
HDFC Bank Ltd - (USD EEFC)	809.06		
In Overdraft Account (debit balance)	-	-	
In Deposit Accounts:			
Fixed deposits having maturity of less than 3 months	-	-	
Other Bank Balances:			
Fixed deposits having maturity of more than 3 months	5,017.64	4,846.14	
Fixed deposits having maturity of more than 12 months	152.94	150.94	
Cheques, drafts on hand	-	-	
Cash on hand	208.62	128.44	
Others - Unpaid dividend	-	-	
<b>Sub total</b>	<b>6,248.13</b>	<b>6,616.19</b>	
Less :Fixed deposits having maturity of more than 12 months (included in Note no. 19 - Other Non Current Assets)	152.94	150.94	
<b>TOTAL Rs.</b>	<b>6,095.19</b>	<b>6,465.25</b>	
NOTE : 22.1 Details of fixed deposits pledged with banks		Amount in ` '000	
Particulars	As at March 31, 2022	As at March 31, 2021	
Fixed deposits pledged with banks as security against credit facilities	-	-	
Fixed deposits pledged with banks as security against overdraft facility	-	-	
<b>TOTAL Rs.</b>	<b>-</b>	<b>-</b>	
NOTE : 23 Short term loans and advances		Amount in ` '000	
Particulars	As at March 31, 2022	As at March 31, 2021	
<b>(Secured / Unsecured Considered Good)</b>			
<b>Repayable on demand :</b>			
Loans & advances to Promoters, Directors, KMPs and Related parties	-	-	
Loans & advances to others	-	-	
Balance with Revenue Authorities	1,97,924.62	1,89,535.78	
Taxes paid in advance (Net)	9,165.20	3,721.64	
MAT credit entitlement	1,779.86	1,779.86	
Advances to suppliers	1,416.73	280.15	
Advances to Staff	141.17	45.00	
Prepaid expenses	1,676.76	2,330.39	
Exhibition Subsidy Receivable	-	-	
Interest Income Receivable on FDR	-	-	
Considered Doubtful	-	-	
Less : Provisions for doubtful loans and advances	-	-	
<b>TOTAL Rs.</b>	<b>2,12,104.33</b>	<b>1,97,692.82</b>	
NOTE : 23.1		Amount in ` '000	
Details of Loans & Advances to Promoters, Directors, KMPs and Related parties <b>Type of Borrower</b>	Amount of loan or advances in the nature of loan outstanding		Percentage to total loans and Advances in the nature of loan
	As at March 31, 2022	As at March 31, 2021	As at March 31, 2022 As at March 31, 2021
Promoters	-	-	0% 0%
Directors	-	-	0% 0%
KMPs	-	-	0% 0%
Related Parties	-	-	0% 0%



<b>NOTE : 24</b>	<b>As at</b>	<b>As at</b>
<b>Other current assets</b>	<b>March 31, 2022</b>	<b>March 31, 2021</b>
Unbilled revenue	-	-
Unamortized premium on forward contracts	-	-
<b>TOTAL Rs.</b>	<b>-</b>	<b>-</b>
<b>Amount in ` '000</b>		
<b>NOTE : 25</b>	<b>Year ended</b>	<b>Year ended</b>
<b>Revenue from operations</b>	<b>March 31, 2022</b>	<b>March 31, 2021</b>
<b>Gross Sales of Products:</b>	<b>7,69,777.13</b>	<b>7,17,767.57</b>
Sale of Goods	5,09,029.14	4,53,368.52
Sale of Exports Goods	2,10,690.26	1,93,958.20
Sale of Trading Goods (Export + Domestic)	40,560.38	59,522.39
Sample Sales	50.22	106.50
Jobwork Income	9,447.13	10,811.96
Less : GST	64,527.34	77,406.97
Less : sales return	-	-
<b>Net Sales</b>	<b>7,05,249.79</b>	<b>6,40,360.59</b>
<b>Other operating revenues</b>		
Wind Farm Unit Generation Income	4,527.19	3,906.44
Export Incentive	2,710.86	8,138.48
Dossier Income	92,119.23	75,894.06
Product permission income	179.09	-
Liquidated Damages	-	36,180.75
Freight on Sales	1,986.88	2,778.64
	<b>1,01,523.26</b>	<b>1,26,898.36</b>
<b>Less : GST</b>	<b>10,208.06</b>	<b>17,393.87</b>
	<b>91,315.20</b>	<b>1,09,504.49</b>
<b>TOTAL RS.</b>	<b>7,96,564.99</b>	<b>7,49,865.09</b>
<b>Sale of Products comprises</b>		
<b>Amount in ` '000</b>		
<b>Class of Goods</b>	<b>March 31, 2022</b>	<b>March 31, 2021</b>
Capsules	67,725.92	50,627.42
Tablets	4,44,696.01	4,14,222.17
Liquid	94,010.89	95,562.78
KIT / Pouch	10,564.93	15,260.53
Injection	64,379.33	55,034.17
Others	15,400.00	-
<b>TOTAL RS.</b>	<b>6,96,777.08</b>	<b>6,30,707.06</b>
<b>Amount in ` '000</b>		
<b>NOTE ; 26</b>	<b>Year ended</b>	<b>Year ended</b>
<b>Other income</b>	<b>March 31, 2022</b>	<b>March 31, 2021</b>
Interest income	195.47	321.22
Foreign Exchange Gain / Loss	2,937.14	591.72
Sale of Scrap	1,094.70	44.72
Sundry Balance Written off	-	413.52
Profit on Sale of Assets	-	263.25
Reimbursement of Expenses	3,805.92	272.11
Commission Income	-	40,970.78
Factory Space Utilisation Income	363.44	726.88
Bus Fair Income	135.40	-
Notice Pay Income	172.58	-
	<b>8,704.66</b>	<b>43,604.20</b>
<b>Less : GST</b>	<b>1,579.06</b>	<b>6,490.58</b>
<b>TOTAL RS.</b>	<b>7,125.60</b>	<b>37,113.62</b>





		Amount in ` '000	
<b>NOTE ; 27</b>		<b>Year ended</b>	<b>Year ended</b>
<b>Cost of material consumed</b>		<b>March 31, 2022</b>	<b>March 31, 2021</b>
<b>(a) Raw materials consumed</b>			
Opening Stock		44,300.47	44,787.53
Add; Purchases (including purchase expenses)		4,54,169.87	3,34,453.14
Less: Closing Stock		73,891.10	44,300.47
Less: Goods in Transit		58,156.38	799.15
<b>TOTAL RS.</b>		<b>3,66,422.86</b>	<b>3,34,141.05</b>
<b>NOTE ; 28</b>		<b>Year ended</b>	<b>Year ended</b>
<b>Cost of material consumed</b>		<b>March 31, 2022</b>	<b>March 31, 2021</b>
<b>(b) Packing materials consumed</b>			
Opening Stock		21,530.31	23,295.03
Add; Purchases (including purchase expenses)		1,53,220.02	1,35,882.48
Less: Closing Stock		28,150.42	21,530.31
Less: Goods in Transit		358.30	530.80
<b>TOTAL RS.</b>		<b>1,46,241.61</b>	<b>1,37,116.40</b>
<b>Details of Material Purchased</b>		<b>Amount in ` '000</b>	
<b>Class of Goods</b>		<b>March 31, 2022</b>	<b>March 31, 2021</b>
Capsules		8,711.32	4,912.88
Powder		4,41,334.78	3,25,413.22
Liquid		3,777.81	2,789.30
Others		252.77	1,337.73
<b>TOTAL RS.</b>		<b>4,54,076.69</b>	<b>3,34,453.14</b>
		<b>Amount in ` '000</b>	
<b>NOTE : 28</b>		<b>Year ended</b>	<b>Year ended</b>
<b><u>Changes in inventories of finished goods, work-in progress and stock in trade</u></b>		<b>March 31, 2022</b>	<b>March 31, 2021</b>
<b><u>Inventories at the end of the year</u></b>			
Finished Goods		6,966.71	9,503.41
Work-in-progress		11,018.85	11,473.39
Stock-in-trade		-	-
<b><u>Inventories at the beginning of the year</u></b>			
Finished Goods		9,503.41	11,898.05
Work-in-progress		11,473.39	11,850.04
Stock-in-trade		-	-
<b>Net (Increase)/Decrease</b>		<b>2,991.24</b>	<b>2,771.29</b>



Amount in ` '000		
NOTE : 29	Year ended	Year ended
Manufacturing expenses	March 31, 2022	March 31, 2021
Labour Charges	40,433.33	39,436.01
Custom duty	2,302.56	-
Electricity Expenses (GEB)	39,874.38	34,450.89
Fuel Consumption	9,904.09	7,034.52
Stores & Spares	1,753.40	1,595.88
Dies & Punch Charges	228.20	1,082.04
Freight , Octroi & Handling Charges	995.26	1,510.18
Repairs Maintainance to Electrical	1,369.28	1,159.20
Repairs Maintainance to Machinery	12,286.42	6,497.28
Repairs Maintainance to Others	370.80	386.19
Repairs Maintainance to Building	1,601.72	1,380.30
House Keeping Expenses	2,974.92	3,009.86
Insurance Expenses	1,799.89	1,231.95
Laboratory Expenses	6,417.47	5,209.74
Packing Expenses	1,532.03	1,332.88
Transmission Charges for Wheeling	1,633.96	1,480.82
Other Manufacturing Overheads	689.06	622.61
<b>Total</b>	<b>1,26,166.78</b>	<b>1,07,420.34</b>

Amount in ` '000		
NOTE : 30	Year ended	Year ended
Employee benefit expenses	March 31, 2022	March 31, 2021
Salary to Factory Worker	24,587.64	19,589.28
Salary to Admin Staff	3,746.62	2,614.69
Salary to Marketing & Selling	3,446.13	2,088.47
Director Remuneration	7,200.00	-
Apprentice Salary	562.61	201.57
Personel Performance	2,083.67	1,809.57
Ex-Gratia	791.62	534.44
Contribution to Providend Fund & Others	4,660.46	3,672.10
Bonus Paid	2,234.47	1,870.17
Gratuity Expenses	(72.86)	3,675.79
Allowances for factory staff	29,213.57	24,162.37
Allowances for admin and marketing staff	7,740.35	5,472.18
Leave Encashment	723.61	578.11
Retainership Expense	2,565.54	3,834.20
Insurance Premium on Personal Accident Policy	30.77	37.31
Staff Welfare Expenses	4,441.66	2,341.70
City compesatory allowance	-	1,079.14
<b>TOTAL Rs.</b>	<b>93,955.85</b>	<b>73,561.09</b>

Amount in ` '000		
NOTE : 31	Year ended	Year ended
Finance cost	March 31, 2022	March 31, 2021
Interest expense	43,111.10	42,103.73
Bank Charges	2,752.78	1,716.64
<b>TOTAL Rs.</b>	<b>45,863.88</b>	<b>43,820.36</b>

Amount in ` '000		
NOTE : 32	Year ended	Year ended
Depreciation and amortization expenses	March 31, 2022	March 31, 2021
Depreciation expenses	45,425.34	46,318.48
Amortization expenses	-	-
Provision for impairment	-	-
<b>TOTAL Rs.</b>	<b>45,425.34</b>	<b>46,318.48</b>



Amount in ` '000		
NOTE : 33	Year ended	Year ended
Other expenses	March 31, 2022	March 31, 2021
<b>a) Office and Administrative Overheads</b>		
Telephone Expenses	299.11	268.20
Postage & Courier Expenses	330.29	191.19
Printing & Stationery Expenses	1,045.44	905.48
Legal & Professional	4,814.40	943.94
Computer Expenses	257.75	177.80
Internet Charges	295.42	266.65
Insurance Premium on Vehicles	122.51	145.51
Insurance on Key Persons	216.36	216.36
Insurance on Mediclaim Group Policy (Folter)	468.26	267.42
Application Fess	296.32	103.90
Office Expense	271.42	546.91
Donation	63.00	21.00
Rent Expense	1,026.62	529.56
Vehicle Expenses	288.76	320.78
GST Expense	1,242.27	758.29
Auditor Remuneration	117.00	93.00
Security Charges	132.33	835.14
Consultancy Charges	1,223.84	590.53
Sundry Balance Written off	123.93	2,177.04
Annual Maintenance Charges	513.90	603.46
Loss on Sale of FMS & MEIS License	2,676.12	-
Loss on Sale of Fixed Assets	40.42	44.05
Other Administrative & Office Expenses	961.35	171.10
<b>TOTAL Rs.</b>	<b>16,826.82</b>	<b>10,177.29</b>
<b>b) Sales &amp; Marketing Expenses</b>		
Travelling & Conveyance Expenses	2,612.67	962.01
Commission on Sales	1,173.44	250.56
Exhibition & Seminar Expenses	505.33	-
Marketing Expenses	3,160.73	912.63
Guest Entertainment Expenses	211.28	29.90
Clearing and Forwarding Charges	3,511.50	2,577.88
Business development charges	3,289.96	4,425.26
Discount Expenses	2,401.69	-
Freight (Export)	3,713.18	3,448.72
Other Selling and Distribution Expenses	673.38	914.75
<b>TOTAL Rs.</b>	<b>21,253.14</b>	<b>13,521.70</b>
Amount in ` '000		
NOTE : 33.1	Year ended	Year ended
Remuneration to auditors	March 31, 2022	March 31, 2021
Auditor's Remuneration comprises of		
Audit fees	70.00	60.00
Tax Audit	30.00	20.00
Taxation matters	16.50	12.50
Company Law	-	-
Other Matters	0.50	0.50
Reimbursement of out of pocket expenses	-	-
<b>TOTAL Rs.</b>	<b>117.00</b>	<b>93.00</b>
Amount in ` '000		
NOTE : 34	Year ended	Year
Earning per share	March 31, 2022	March 31, 2021
Profit after Tax	(82,880.52)	(42,975.04)
Weighted average number of equity shares in calculating basic EPS	1,876.64	1,800.00
Nominal value of equity share	Rs 10/-	Rs 10/-
Basic Earning per share of Rs	-44.16	-23.88
Diluted Earning per share of Rs	-44.16	-23.88





**Note 35**
**Related Party Disclosure**
**(I) Related parties and their relationship**
**(a) Key Management Personnel & Relatives**
**(i) Name of the Management Personnel**

1. Jitendra Babulal Sanghvi
2. Kushal Champalal Bhansali
3. Swapnil Jatinbhai Shah
4. Arpit Deepakkumar Shah

**Type**

- Director
- Director
- Director
- Director

**(ii) Name of Relative**

1. Babulal M Sanghvi - HUF
2. Shantaben Babulal Sanghvi
3. Pinky Jitendra Sanghvi
4. Anar Swapnil Shah
5. Roma Arpit Shah

**Relation**

- Father of Director
- Mother of Director
- Wife of Director
- Wife of Director
- Wife of Director

**(b) Entities controlled by Directors/ Relatives of Directors:**
**Name of the entities**

- 1) Ratnamani Marketing Private Limited
- 2) Ratnamani Techno Casts Private Limited
- 3) Maniratna Stainless Private Limited
- 4) Adroit Life Science Private Limited
- 5) Kevin Realities LLP
- 6) Remus Pharmaceuticals Private Limited
- 7) Relius Lifesciences Private Limited
- 8) Healthy Life Nutraceuticals Private Limited
- 9) Espee Life Science Private Limited
- 10) Ratnagene Lifescience Private Limited
- 11) Senores Pharmaceuticals Private Limited
- 12) Renosen Pharmaceuticals Private Limited
- 13) Senores Lifesciences Private Limited
- 14) Espee Therapeutics LLP
- 15) Calypso Hospitality LLP
- 16) Sumer Enterprises LLP
- 17) Aelius Projects LLP
- 18) Biopapro Cutleries Private Limited

**Amount in ` '000**
**(II) Transactions with related parties**

Particulars	Year ended March 31,2022	Year ended March 31,2021
Purchase of Assets- Land, Building, Plant & Machinery, Furniture & Fixtures, Vehicle, Computers & Intangible Assets	-	-
Sales of Assets / Others	-	-
Rendering Services	-	-
Interest Income	-	-
Interest Paid to Directors	-	-
Interest Paid to Related Parties	13,729.46	8,026.16
Receipt of Services	-	-
Purchase of Goods	1,13,418.78	35,338.96
Sale of Goods	15,992.29	17,797.59
Other Income	41,582.20	58,183.91
Liquidated Damages	-	36,180.75
Reimbursements of Expenses	-	-
Share of Profit/(Loss) from Partnership Firm	-	-
Director's Sitting Fees Paid	-	-
Director Remuneration	7,200.00	-
Investment in Equity of Subsidiary	-	-
Impairment on Loan / Investment	-	-
Loan Received	1,65,091.25	4,08,705.62
Loan Repaid	73,145.87	3,33,851.21

**Amount in ` '000**
**(III) Outstanding Balances arising from sales/purchase of goods/services with related parties**

Particulars	Year ended March 31,2022	Year ended March 31,2021
Investment	-	-
Loans from Related Parties	3,65,386.32	10,01,375.33
Trade Payables	52,535.46	22,512.98
Other Financial Assets (Interest Receivable)	-	-
Remuneration Payable	600.00	-



NOTE : 36		Amount in ` '000
Value of imports calculated on C.I.F. basis (If there is any import of C.I.F. basis, value to be given for: Raw Materials, components and spare parts and capital goods)	-	1,661.04

Amount in ` '000				
NOTE : 37 Expenditure in foreign currency :	Year ended		year ended	
	March 31, 2022		March 31, 2021	
Particulars	Foreign Currency	Equivalent Indian Currency	Foreign Currency	Equivalent Indian Currency
Interest	-	-	-	-
Royalty	-	-	-	-
Know-how	-	-	-	-
Professional and consultancy fee	39.31	2,961.83	19.50	1,237.07
Other Expenses	18.26	1,236.15	-	-
<b>Other matters</b>				
Raw Material	-	-	21.85	1,661.04
Stores & Spares	-	-	-	-
Capital Goods	-	-	-	-
<b>Total</b>	<b>57.57</b>	<b>4,197.98</b>	<b>41.35</b>	<b>2,898.10</b>

Amount in ` '000				
NOTE : 38 Value of imported and indigenous raw materials, spareparts and components	Year ended		Year ended	
	March 31, 2022		March 31, 2021	
Particulars	Foreign Currncy	Equivalent Indian Currency	Foreign Currncy	Equivalent Indian Currency
Imported	-	-	21.85	1,661.04
Indigenous	-	4,54,169.87	-	3,32,737.13
<b>Total</b>	<b>-</b>	<b>4,54,169.87</b>	<b>21.85</b>	<b>3,34,398.17</b>

NOTE : 39 Earnings in foreign currency			Amount in ` '000
i) Export of goods calculated on F.O.B. basis	2,25,974.61		2,10,572.08
ii) Export of Service calculated on F.O.B. basis	38,043.00		-
iii) Royalty, know-how, professional and consultation	-		-
Interest and dividends	-		-
v) Other income indicating the nature thereof	-		-



**Note 40**

**Additional regulatory information**

**(a) Ratios**

Ratios	Numerator	Denominator	As at March 31, 2022	As at March 31, 2021	Variance	Explanation for any change in the ratio by more than 25% as compared to the preceding year.
(a) Current ratio	Current assets	Current liabilities	1.49	1.63	-0.15	
(b) Debt-equity ratio	Total debt	Shareholders' equity	7.03	-6.15	13.18	
(c) Debt service coverage ratio	Earnings available for debt service	Debt service	0.00	0.02	-0.03	
(d) Return on equity ratio (in %)	Net profit after taxes less preference dividend (if any)	Average shareholders' equity	160.84%	20.29%	1.41	
(e) Inventory turnover ratio	Cost of goods sold or sales	Average inventory	5.97	8.33	-2.36	
(f) Trade receivables turnover ratio	Net credit sales	Average trade receivables	3.12	4.07	-0.94	
(g) Trade payables turnover ratio	Net credit purchases	Average trade payables	1.74	2.05	-0.31	
(h) Net capital turnover ratio	Net sales	Average working capital	3.74	5.03	-1.30	
(i) Net profit ratio (in %)	Net Profit after taxes	Net sales	-10.40%	-5.73%	-0.05	
(j) Return on capital employed (in %)	Earning before interest and taxes	Capital employed	-4.58%	-1.13%	-0.03	
(k) Return on investment (in %)	Income from investments	Cost of investment	-	-	-	

**NOTE : 40 (b)**

Particulars relating to corporate social responsibility

The Clause is not applicable to the Company.





**NOTE : 40 (c)****Particulars of transactions with companies struck off under section 248 of the**

The Company do not have any transactions with companies struck off.

**NOTE : 40 (d)****Details of benami property held**

The Company do not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.

**Note : 40 (e)****Compliance with number of layers of companies :**

The Company does not have any subsidiary.

**NOTE : 40 (f)****Compliance with approved Scheme(s) of Arrar**

Company has prepared a Scheme of Compromised and Arrangements in terms of sections 230 read with section 66 along with other applicable provisions of the Companies Act, 2013, the scheme of Compromised and arrangement has applied to the Competent Authority in terms of Sections 230 to 237, effect of such scheme as approved by Honorable NCLT by order dt 20/09/2022 and its effects in terms of Rupee for each item is as under.

Particulars	Effect in Rs.
1. 10 % Reduction in Share Capital	18,00,000.00
2. Fresh Issue of Equity Share Capital	25,66,364.00
3. Increased in Security Premium	2,56,63,636.00
4. 10 % Decreased in Security Premium	1,79,90,000.00
5. Zero coupon Non-Convertible Debentures (NCDs)	22,00,00,000.00
6. Reducetion Unsecured Loans	78,46,00,000.00
7. Reduction in Accumulated Losses	43,12,24,358.00
8. Reduction in Plant and Machinery	10,68,89,385.00
9. Reduction in Inventories	75,00,000.00
10. Provision of Retirement Benefits	25,00,000.00
11. Reduction in Misc Deposit	12,42,021.00
12. Reduction in GST Receivable	10,71,85,926.00
13. Reduction in Deferred Tax Assets	7,24,03,551.00
14. Reduction in sticky / slow moving / non moving Debtors	4,04,10,523.00

after giving above effect the Capital Reserve fund stands at Rs. 68,04,236/-

**NOTE : 40 (g)****Utilisation of borrowed funds and Share Premium**

a ) During the year, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

b) During the year, no funds have been received by the Company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

**NOTE : 41**

Figures of previous year have been recasted / restated where necessary.

**The notes on account form integral part of the financial statements 1 to 41**

For RAJESH J. SHAH & ASSOCIATES

Chartered Accountants

Firm Registration No. 108407W

CA RAJESH J. SHAH

PARTNER

Membership No : 040268

UDIN :

Place : Ahmedabad

Date : 23rd September, 2022




For, RATNATRIS PHARMACEUTICALS PVT. LTD

For and on behalf of the Board of Directors

  
JITENDRA B. SANGHAVI  
Director

DIN NO.: 00271995

  
SWAPNIL J. SHAH  
Director

DIN NO.: 05259821

Place : Ahmedabad

Date : 23rd September, 2022

# RATNATRISH PHARMACEUTICALS PVT LTD

## ANNEXURE F : ACCOUNTING RATIOS

NO	PARTICULARS	2021-22	2020-21
1	<b>GROSS PROFIT RATIO</b> Sales including Operating Income Increase/dec in stock <b>TOTAL - A</b>  Raw Material Consumption Trading Purchase Manufacturing Overheads Employees Cost <b>TOTAL - B</b>  Gross profit A-B <b>GROSS PROFIT/TURNOVER %</b> <b>decrease in GP</b>	79,65,64,988 -29,91,239 <b>79,35,73,749</b>  51,26,64,476 3,23,19,950 12,61,66,777 7,20,15,566 <b>74,31,66,769</b>  5,04,06,980 <b>6.33%</b>	74,98,65,085 -27,71,288 <b>74,70,93,797</b>  47,12,57,441 7,55,27,742 10,74,20,342 5,72,09,843 <b>71,14,15,369</b>  3,56,78,428 <b>4.76%</b>
2	<b>NET PROFIT/TURNOVER %</b> Sales Net Profit <b>NET PROFIT/TURNOVER %</b>	79,65,64,988 -9,37,76,898 <b>-11.77%</b>	74,98,65,085 -5,73,97,025 <b>-7.65%</b>
3	<b>STOCK IN TRADE/TURNOVER %</b>  Closing Stock of Finished Goods Turnover <b>STOCK IN TRADE/TURNOVER %</b>	  69,66,714 79,65,64,988 <b>0.87%</b>	  95,03,414 74,98,65,085 <b>1.27%</b>
4	<b>MATERIAL CONSUMED/FINISHED GOODS PRODUCED</b>  Raw Material Consumed TOTAL - A  Raw Material Consumed Packing Material Consumed Manufacturing Overheads Employees Cost TOTAL ADD : Opening Stock of W.I.P TOTAL Less : Closing Stock of W.I.P <b>Finished Goods Produced</b> <b>MATERIAL CONSUMED/FINISHED GOODS PRODUCED</b>	  36,64,22,862 <b>36,64,22,862</b>  36,64,22,862 14,62,41,614 12,61,66,777 7,20,15,566 <b>71,08,46,819</b> 1,14,73,393 <b>72,23,20,212</b> 1,10,18,854 <b>71,13,01,358</b> <b>51.51%</b>	  33,41,41,046 <b>33,41,41,046</b>  33,41,41,046 13,71,16,395 10,74,20,342 5,72,09,843 <b>63,58,87,626</b> 1,18,50,041 <b>64,77,37,667</b> 1,14,73,393 <b>63,62,64,274</b> <b>52.52%</b>

